Skip to main content
Clinical Trials/NCT03551197
NCT03551197
Unknown
Phase 4

Impact of Exercise on Lung Function in Patients With Chronic Obstructive Pulmonary Disease

Zhujiang Hospital1 site in 1 country50 target enrollmentJune 13, 2018

Overview

Phase
Phase 4
Intervention
Budesonide and formoterol bid
Conditions
Pulmonary Disease, Chronic Obstructive
Sponsor
Zhujiang Hospital
Enrollment
50
Locations
1
Primary Endpoint
Changes of forced expired volume in one second(FEV1) after 6-min walk test compared with resting state
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the changes of lung function before and after the exercise in patients with chronic obstructive pulmonary disease.The assessment of quality of life is also carried out through questionnaires.

Detailed Description

This is a randomized,open-label study to research the changes of lung function before and after exercise in patients with chronic obstructive pulmonary disease .At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),Clinical Chronic Obstructive Pulmonary Questionnaire(CCQ) and chronic obstructive pulmonary assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.

Registry
clinicaltrials.gov
Start Date
June 13, 2018
End Date
September 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Zhujiang Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female patients 18 to 80 years-old, inclusive.
  • A clinical diagnosis of chronic obstructive pulmonary disease according to the Global Initiative for Chronic Obstructive Disease(GOLD 2018) guidelines.
  • Post bronchodilator (following inhalation of salbutamol) forced expired volume in one second(FEV1)/forced vital capacity(FVC) ratio ≤0.
  • Willing and able to provide written informed consent.
  • Willing and able to attend all study visits and adhere to all study assessments and procedures.

Exclusion Criteria

  • Severe comorbidities including unstable cardiac or pulmonary disease or any other medical conditions including unstable ischemic heart disease,unstable cardiac arrhythmia or heart failure,life threatening arrhythmias,etc.
  • Recent history of chronic obstructive pulmonary disease exacerbation requiring hospitalization or need for increased treatments for chronic obstructive pulmonary disease within 6 weeks.

Arms & Interventions

Budesonide and formoterol bid

At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.

Intervention: Budesonide and formoterol bid

Outcomes

Primary Outcomes

Changes of forced expired volume in one second(FEV1) after 6-min walk test compared with resting state

Time Frame: At resting state and after 6-min walk test

Forced expired volume in one second(FEV1) is measured by Jaeger MasterScreen Pulmonary Function Test System before and after 6-min walk test.

Secondary Outcomes

  • Changes of inspiratory capacity(IC) after 6-min walk test compared with resting state(At resting state and after 6-min walk test)
  • Changes of blood oxygen saturation after 6-min walk test compared with resting state(At resting state and after 6-min walk test)
  • Changes of pulse after 6-min walk test compared with resting state(At resting state and after 6-min walk test)
  • Changes of inspiratory capacity(IC) after 3 months' treatment compared with baseline(Change from baseline to 3 months)
  • Changes of diffusion function after 3 months' treatment compared with baseline(Change from baseline to 3 months)
  • Changes of modified Medical Research Council dyspnoea scale(mMRC) scores after 3 months' treatment compared with baseline(Change from baseline to 3 months)
  • Changes of St George's Respiratory Questionnaire(SGRQ) scores after 3 months' treatment compared with baseline(Change from baseline to 3 months)
  • Changes of impulse forced oscillometry parameters after 3 months' treatment compared with baseline(Change from baseline to 3 months)
  • Changes of clinical chronic obstructive pulmonary questionnaire(CCQ) scores after 3 months' treatment compared with baseline(Change from baseline to 3 months)
  • Changes of chronic obstructive pulmonary disease assessment test(CAT) scores after 3 months' treatment compared with baseline(Change from baseline to 3 months)
  • The distance and steps of 6-min walk test(Change from baseline to 3 months)
  • Changes of forced expired volume in one second(FEV1) after 3 months' treatment compared with baseline(Change from baseline to 3 months)

Study Sites (1)

Loading locations...

Similar Trials